Assessment of bendamustine-induced genotoxicity in eukaryotic cells

References

• Ahmed, F., et al., 1999. In vitro activation of irinotecan to SN-38 by human liver and intestine. Anticancer Research, 19, 2067–2071.
   PubMed Web of Science ®Google Scholar
• Alzoubi, K., et al., 2012. Evaluation of vitamin B12 effects on DNA damage induced by pioglitazone. Mutation Research, 748, 48–51.
   PubMed Web of Science ®Google Scholar
• Bonassi, S., et al., 2011. Micronuclei frequency in peripheral blood lymphocytes and cancer risk: evidence from human studies. Mutagenesis, 26, 93–100.
   PubMed Web of Science ®Google Scholar
• Bonassi, S., et al., 2000. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on cytogenetic biomarkers and health. Cancer Research, 60, 1619–1625.
   PubMed Web of Science ®Google Scholar
• Cephalon Inc., 2008. Treanda^® (bendamustine hydrochloride) for injection, for intravenous infusion [online]. Avaliable from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022249lbl.pdf [Accessed 12 April 2016].
   Google Scholar
• Chandrasekaran, C.V., et al., 2009. Evaluation of the genotoxic potential and acute oral toxicity of standardized extract of Andrographis paniculata (KalmColdTM). Food and Chemical Toxicology, 47, 1892–1902.
   PubMed Web of Science ®Google Scholar
• Cheson, B.D. and Rummel, M.J., 2009. Bendamustine: rebirth of an old drug. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 1492–1501.
   PubMed Web of Science ®Google Scholar
• Dertinger, S.D., et al., 2014. Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapy. Toxicological Sciences: An Official Journal of the Society of Toxicology, 140, 307–314.
   PubMed Web of Science ®Google Scholar
• Domingues Zucchi, T., et al., 2005. A short-term test adapted to detect the genotoxic effects of environmental volatile pollutants (benzene fumes) using the filamentous fungus Aspergillus nidulans. Journal of Environmental Monitoring, 7, 598–602.
   PubMedGoogle Scholar
• Esquissato, G.N., et al., 2014. Gene homozygosis and mitotic recombination induced by camptothecin and irinotecan in Aspergillus nidulans diploid cells. Anais Da Academia Brasileira De Ciências, 86, 1703–1710.
   PubMed Web of Science ®Google Scholar
• Fenech, M., 2000. The in vitro micronucleus technique. Mutation Research, 455, 81–95.
   PubMed Web of Science ®Google Scholar
• Fenech, M., 2007. Cytokinesis-block micronucleus cytome assay. Nature Protocols, 2, 1084–1104.
   PubMed Web of Science ®Google Scholar
• Friedberg, J.W., et al., 2008. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26, 204–210.
   PubMed Web of Science ®Google Scholar
• Gandhi, V., 2002. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Seminars in Oncology, 29, 4–11.
   PubMed Web of Science ®Google Scholar
• Gaul, L., et al., 2008. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. Journal of Cancer Research and Clinical Oncology, 134, 245–253.
   PubMed Web of Science ®Google Scholar
• Gentile, M., et al., 2015. Bendamustine in multiple myeloma. European Journal of Haematology, 95, 377–388.
   PubMed Web of Science ®Google Scholar
• Hartmann, M. and Zimmer, C.H., 1972. Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochimica Et Biophysica Acta, 287, 386–389.
   PubMed Web of Science ®Google Scholar
• Hosing, C., et al., 2002. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 13, 450–459.
   PubMed Web of Science ®Google Scholar
• Kašuba, V., et al., 2010. Assessment of cyto/genotoxicity of irinotecan in V79 cells using the comet, micronucleus, and chromosome aberration assay. Archives of Industrial Hygiene and Toxicology, 61, 1–9.
   PubMed Web of Science ®Google Scholar
• Khan, F., Sherwani, A.F., and Afzal, M., 2009. Chromosomal aberration and micronucleus studies of two topoisomerase (II) targeting anthracyclines. Journal of Environmental Biology, 30, 409–412.
   PubMed Web of Science ®Google Scholar
• Kirsch-Volders, M., et al., 2011. The in vitro Mn assay in 2011: origin and fate, biological significance, protocols, high throughput methodologies and toxicological relevance. Archives of Toxicology, 85, 873–899.
   PubMed Web of Science ®Google Scholar
• Konstantinov, S.M., et al., 2002. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. Journal of Cancer Research and Clinical Oncology, 128, 271–278.
   PubMed Web of Science ®Google Scholar
• Leoni, L.M., et al., 2008. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 14, 309–317.
   PubMed Web of Science ®Google Scholar
• Leoni, L.M., 2011. The evolving role of bendamustine in lymphoid malignancy: understanding the drug and its mechanism of action. Seminars in Hematology, 48, S1–S3.
   PubMed Web of Science ®Google Scholar
• Lorge, E., et al., 2008. Comparison of different methods for an accurate assessment of cytotoxicity in the in vitro micronucleus test. I. Theoretical aspects. Mutation Research, 655, 1–3.
   PubMed Web of Science ®Google Scholar
• Lorge, E., et al., 2006. SFTG international collaborative study on in vitro micronucleus test I. General conditions and overall conclusions of the study. Mutation Research, 607, 13–36.
   PubMed Web of Science ®Google Scholar
• Maenosono, S., Yoshida, R., and Saita, S., 2009. Evaluation of genotoxicity of amine-terminated water-dispersible FePt nanoparticles in the Ames test and in vitro chromosomal aberration test. The Journal of Toxicological Sciences, 34, 349–354.
   PubMed Web of Science ®Google Scholar
• Merchionne, F., et al., 2014. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. Leukemia Research, 38, 1446–1450.
   PubMed Web of Science ®Google Scholar
• Merli, M., et al., 2013. Novel agents in indolent lymphomas. Therapeutic Advances in Hematology, 4, 133–148.
   PubMedGoogle Scholar
• Miyamoto, C.T., et al., 2007. Genotoxicity (mitotic recombination) of the cancer chemotherapeutic agents cisplatin and cytosine arabinoside in Aspergillus nidulans. Food and Chemical Toxicology, 45, 1091–1095.
   PubMed Web of Science ®Google Scholar
• Momota, H., et al., 2013. Secondary hematological malignancies associated with temozolomide in patients with glioma. Neuro-oncology, 15, 1445–1450.
   PubMed Web of Science ®Google Scholar
• Morais, J.F., et al., 2016. Genotoxic investigation of a thiazolidinedione PPARγ agonist using the in vitro micronucleus test and the in vivo homozygotization assay. Mutagenesis, 31, 417–424.
   PubMed Web of Science ®Google Scholar
• Moynahan, M.E. and Jasin, M., 2010. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nature Reviews Molecular Cell Biology, 11, 196–207.
   PubMed Web of Science ®Google Scholar
• Natarajan, A.T. and Palitti, F., 2008. DNA repair and chromosomal alterations. Mutation Research, 657, 3–7.
   PubMed Web of Science ®Google Scholar
• OECD, Organization for Economic Co-operation and Development, 2016. Test No. 473: In vitro mammalian chromosome aberration test [online]. Available from: http://dx.doi.org/10.1787/9789264264649-en [Accessed 17 January 2017].
   Google Scholar
• OECD, Organization for Economic Co-operation and Development 2016. Test No. 487: in vitro mammalian cell micronucleus test [online]. Available from: http://dx.doi.org/10.1787/9789264264861-en [Accessed 17 January 2017].
   Google Scholar
• Owen, J.S., et al., 2010. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin’s lymphoma. Cancer Chemotherapy and Pharmacology, 6, 1039–1049.
   Google Scholar
• Pendleton, M., et al., 2014. Topoisomerase II and leukemia. Annals of the New York Academy of Sciences, 1310, 98–110.
   PubMed Web of Science ®Google Scholar
• Pereira, T.S., et al., 2014. In vitro genotoxicity of Melaleuca alternifolia essential oil in human lymphocytes. Journal of Ethnopharmacology, 151, 852–857.
   PubMed Web of Science ®Google Scholar
• Pires, L.T. and Zucchi, T.M.A.D., 1994. A new method to detect potential genotoxic agents using mitotic crossing-over in diploid strains of Aspergillus nidulans. Brazilian Journal of Genetics, 17, 371–376.
   Google Scholar
• Rasschaert, M., et al., 2007. A phase I study of bendamustine hydrochloride administered day 1 + 2 every 3 weeks in patients with solid tumours. British Journal of Cancer, 96, 1692–16928.
   PubMed Web of Science ®Google Scholar
• Rivory, L.P., et al., 1996. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochemical Pharmacology, 52, 1103–1111.
   PubMed Web of Science ®Google Scholar
• Rjiba-Touati, K., et al., 2012. Induction of DNA fragmentation, chromosome aberrations and micronuclei by cisplatin in rat bone-marrow cells: protective effect of recombinant human erythropoietin. Mutation Research, 747, 202–206.
   PubMed Web of Science ®Google Scholar
• Rothenberg, M.L., 2001. Irinotecan (CPT-11): recent developments and future directions-colorectal cancer and beyond. The Oncologist, 6, 66–80.
   PubMed Web of Science ®Google Scholar
• Sant’Anna, J.R., et al., 2015. Assessment of in vivo and in vitro genotoxicity of glibenclamide in eukaryotic cells. PLoS One, 10, e0120675.
   PubMed Web of Science ®Google Scholar
• Sant’Anna, J.R., et al., 2013. Metformin’s performance in in vitro and in vivo genetic toxicology studies. Experimental Biology and Medicine (Maywood, N.J.), 238, 803–810.
   PubMed Web of Science ®Google Scholar
• Savage, P., et al., 2015. Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33, 472–479.
   PubMed Web of Science ®Google Scholar
• Sen, P., et al., 1990. Induction of chromosome breaks and sister chromatid exchanges in patients with Hodgkin’s disease by two combination chemotherapy regimens of different leukemogenic potential. Cancer Research, 50, 558–562.
   PubMed Web of Science ®Google Scholar
• Spaans, V.M., et al., 2014. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers. PLoS One, 9, e93451
   PubMed Web of Science ®Google Scholar
• Stewart, D.R., et al., 2012. Mitotic recombination of chromosome arm 17q as a cause of loss of heterozygosity of NF1 in neurofibromatosis type 1-associated glomus tumors. Genes, Chromosomes and Cancer, 51, 429–437.
   PubMed Web of Science ®Google Scholar
• Strumberg, D., et al., 1996. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anti-Cancer Drugs, 7, 415–421.
   PubMed Web of Science ®Google Scholar
• Vlastos, D., et al., 2013. Evaluation of the genotoxic and antigenotoxic effects of chios mastic water by the in vitro micronucleus test on human lymphocytes and the in vivo wing somatic test on drosophila. PLoS One, 8, e69494
   PubMed Web of Science ®Google Scholar
• Zulkowski, K., et al., 2002. Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. Journal of Cancer Research and Clinical Oncology, 12, 111–113.
   Google Scholar